HS-WXAT@EC2607B

JPMorgan Reduces Holding in WuXi Biologics by 798,119 Shares

Goldman Sachs Upgrades WuXi AppTec's A-Share Rating to Buy

WuXi Biologics Announces Strong 2025 Financial Forecast, Revenue and Net Profit Both Up

JPMorgan Cuts Stake in Wuxi Biologics by 2.517805 million Shares

WuXi Biologics Receives Multiple ESG Ratings and Certifications

WuXi AppTec Discloses Business Scale and Global Layout

WuXi AppTec Updates Business Progress at J.P. Morgan Healthcare Conference

WuXi Biologics Announces Latest Progress in GLP-1 Pipeline

WuXi Biologics to issue 584 million new H shares

WuXi Biologics Q4 Earnings Beat Expectations, CLSA Rates 'Outperform'

Wuxi Biologics Expected Net Profit Growth of 41.33% in 2025

JPM 44th Global Healthcare Conference Focuses on Biopharmaceutical Industry Trends

WuXi Biologics Announces 2024H Revenue with Minor Increase

CLSA Maintains Overweight Rating for Wuxi Biologics with Increased Target Price

Controlling Shareholders of Wuxi Biologics Completed the Share Reduction Plan

BlackRock Reduces Stake in WuXi Biologics

Blackstone Increases Its H Shares Stake in Wuxi Biologics to 5.10%

WuXi AppTec's Controlling Shareholder Sells 41.34 Million Shares for 3.8 Billion Yuan in 30 Days

WuXi Biologics Shareholders Reduce Holdings, Stake Drops to 16.97%

GUANZE MEDICAL

TJCD

ASIA ENERGY LOG

CHI P ENERGY

BOER POWER

AB BUILDERS

SUN HING PRINT

NIU HOLDINGS

HUAYUEXPRESSWAY

ZHONGSHI MINAN

603259

02268

02359

Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data and earnings visibility. Positive on CDMO companies, upgrading WuXi AppTec and WUXI XDC ratings to "Buy." A selective strategy is recommended for biotech and pharmaceutical companies, recommending SKB BIO-B, HENLIUS, and HANSOH PHARMA. The medical device sector maintains a neutral stance, recommending ANGELALIGN and WEIGAO GROUP. A cautious attitude is taken towards the medical services sector, downgrading HYGEIA HEALTH and JXR ratings

AASTOCKS

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

HANSOH PHARMA

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

SKB BIO-B

ChinaAMC SSE STAR Biology and Medicine ETF

KELUN PHARMA

HENLIUS

WEIGAO GROUP

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP CSI Pharmaceuticals ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

HYGEIA HEALTH

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

WuXi AppTec

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ANGELALIGN

Dacheng CSI All Share Health Care Equipment and Services ETF

Hwabao WP CSI Medical Service ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

WUXI XDC

Ping An CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

WUXI APPTEC

Bosera Hang Seng SCHK Innovative Drug Select ETF

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

09987

03288

00992

09660

00100

01772

01208

03993

00358

YUM CHINA(09987) rose 11.42%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 18.6%. HAITIAN FLAV(03288) rose 5.59%, with a trading turnover 394.2 Million HKD, and a year-to-date rose 3.8%. MINIMAX-WP(00100) fell 8.65%, with a trading turnover 675.2 Million HKD, and a year-to-date rose 194.5%. GANFENGLITHIUM(01772) fell 6.6%, with a trading turnover 1.2 Billion HKD, and a year-to-date rose 7.6%.

Top Gainers & Losers

YUM CHINA

HAITIAN FLAV

LENOVO GROUP

HORIZONROBOT-W

MINIMAX-WP

GANFENGLITHIUM

CMOC

JIANGXI COPPER

Top 5 HK Stock Gainers/Losers (>100B) (2.5)

OpenAI's CEO Altman: The company may seek partners or invest in AI drug discovery

Wallstreetcn

Relay Therapeutics

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ALPS Medical Breakthrough

Lantern Pharma

YieldMax AI Option Income Strategy ETF

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

Yinhua CNI HK Connect Innovative Drugs ETF

Recursion Pharmaceuticals

Abcellera Biologics

Tempus AI

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

ChinaAMC CSI All Share Health Care Devices ETF

Exact Sciences

Marinus Pharma

iShares US Pharma

Tianhong CNI BIOMEDICINE ETF

VanEck Biotech ETF

iShares US Healthcare Providers

Ark Genomic Revolution ETF

SPDR S&P Health Equip

PHARMARON

Neumora Therapeutics

Absci

Health Care Select Sector SPDR

Moderna

VG Health

The State Council has announced the newly revised "Regulations for the Implementation of the Drug Administration Law," which will take effect on May 15, 2026. This is the first comprehensive revision of the regulations in over twenty years. The key points of the revision include: improving the drug registration system, establishing exclusive market periods for pediatric drugs and drugs for rare diseases for the first time (up to 2 years and 7 years respectively), clarifying four new drug expedited approval pathways; strengthening the responsibilities of online drug trading platforms and regulating online drug sales; allowing segmented commissioning of innovative drug production to optimize the industrial supply chain; and shifting the regulatory focus from enterprises to drug marketing authorization holders, enhancing lifecycle supervision

- On January 27, Premier Li Qiang signed a decree announcing the revised Implementation Regulations of the Drug Administration Law, effective May 15, 2026.  
- The updated regulations, marking the first comprehensive revision in over 20 years, enhance drug research, approval processes, and production management, while emphasizing innovation and public access to safe medications.  
- Key changes include support for pediatric and rare disease drug exclusivity periods, stringent online sales regulations, and the introduction of a segmented production system to boost production efficiency.

Yinhua CSI Research Sector 100 ETF

BeOne Medicines

CSPC PHARMA

JD HEALTH

CSPC Innovation

Pharmaron

Beigene

Guotai SSE STAR Brand Name Drug ETF

Tigermed

SINO BIOPHARM

New Drug Administration Implementation Regulations Released: Allowing Innovative Drugs to be Produced in Segments, Accelerating the Market Launch of Good Medicines

03696

02228

02269

INSILICO fell 11.58%; Jingtao Holdings fell 6.23%, with a transaction volume of HKD 792 million; WuXi Biologics fell 3.36%, with a transaction volume of HKD 442 million; WuXi AppTec fell 0.96%, with a transaction volume of HKD 323 million; WuXi Huilian fell 3.71%, with a market value of HKD 83.2 billion

HK Stock Movers Tracker

INSILICO

XTALPI

WUXI BIO

Hong Kong Stock Movement: INSILICO approved by FDA but fell 11.58%, leading stocks in the life sciences sector under pressure

09992

03986

02259

01055

02628

01276

01211

00981

00763

POP MART(09992) rose 9.07%, with a trading turnover 5.9 Billion HKD, and a year-to-date rose 5.1%. GIGADEVICE(03986) rose 5.52%, with a trading turnover 532.3 Million HKD, and a year-to-date rose 88.9%. HENGRUI PHARMA(01276) fell 4.36%, with a trading turnover 161.0 Million HKD, and a year-to-date rose 3.2%. WUXI APPTEC(02359) fell 4.13%, with a trading turnover 672.1 Million HKD, and a year-to-date rose 15.2%.

- The Hang Seng Index decreased by 0.29%, with a year-to-date increase of 3.3%; the Hang Seng Tech Index dropped by 1.16%, also with a 3% rise this year.  
- Pop Mart (09992) rose by 9.07%, achieving a trading volume of 5.88 billion HKD and a year-to-date increase of 5.1%.  
- In contrast, companies like Innovent Biologics (01276) and WuXi AppTec (02359) saw declines of 4.36% and 4.13% respectively, with year-to-date increases of 3.2% and 15.2%.

POP MART

GIGADEVICE

ZIJIN GOLD INTL

CHINA SOUTH AIR

CHINA LIFE

HENGRUI PHARMA

BYD COMPANY

SMIC

Top 5 HK Stock Gainers/Losers (>100B) (1.20)

XPEV

09868

02126

01299

Morgan Stanley released a global thematic investment report, emphasizing the importance of thematic research, believing it can identify attractive investment opportunities amid market volatility. The four core themes for 2026 are technology diffusion, the future of energy, a multipolar world, and social transformation. The thematic investment stock list for the Asia-Pacific region includes AIA, Tencent, WuXi AppTec, XPeng, and others

XPeng

XPENG-W

JW THERAP-B

Morgan Stanley lists thematic investment stock list for the Asia-Pacific region (including Japanese stocks) (table)

Jiangyin International raised the target price for WUXI XDC to 91 yuan and increased the net profit forecast for 2025 by 2% to 3%. The company expects revenue to grow by more than 45% in 2025, with gross profit increasing by more than 70%, benefiting from order growth and improved production efficiency. A total of 70 new comprehensive CMC projects were signed, bringing the total number of projects to 252 by the end of the year, maintaining a "Buy" rating and outlook for long-term high growth certainty

CITIC International raised the target price of WuXi XDC to 91 yuan and upgraded earnings forecasts

WuXi AppTec Co. Ltd. has received the MSCI AAA ESG rating and has been recognized on the CDP 'A List' for its leadership in climate change and water security. The company has achieved the highest ratings in both categories, reflecting its commitment to sustainability. WuXi AppTec has been included in the Dow Jones Sustainability Index and the FTSE4Good Index, and has received a Gold Medal from EcoVadis for sustainability. Additionally, its emissions reduction targets have been validated by the Science Based Targets initiative.

Reuters

WuXi AppTec Receives MSCI AAA ESG Rating and CDP 'A' Scores for Climate and Water

On January 16th, the three major indices of the Hong Kong stock market experienced slight adjustments, with the Hang Seng Index and the Hang Seng TECH Index retreating slightly, and the previous gains failing to continue. Mainstream sectors showed divergence, with retail and internet leaders exhibiting fluctuating performances. Short-term capital focused on technology and high-tech concepts, with notable gains in popular stocks such as MINIMAX-WP and SYNAGISTICS. The market is highly sensitive to liquidity, macroeconomic recovery, and corporate profit expectations, with an overall moderate risk appetite

- On January 16, Hong Kong stocks showed slight adjustments, with the Hang Seng Index closing at 26,844.96, down 0.29%.  
- Market activity was cautious amid mixed performance in various sectors, particularly in retail and technology, with significant stock movements driven by AI and recent IPO activities.  
- Investors remain focused on economic recovery indicators and corporate earnings amid rising sensitivity to interest rates and liquidity.

Market Heartbeat

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

Hang Seng TECH Index

BABA-W

JD-SW

MNSO

TENCENT

BIDU-SW

KUAISHOU-W

CITIC RESOURCES

SHENGHUI CLEAN

XIAOMI-W

SYNAGISTICS

Hong Kong Stock Market Closing | The Hang Seng Index fell 0.29%, with a divergence in the technology and retail sectors, while popular stocks like MINIMAX-WP surged significantly

The main indices of the Hong Kong stock market experienced slight adjustments during the trading session, with the Hang Seng Index, Hang Seng Tech Index, and the China Enterprises Index all retreating, reflecting a strong wait-and-see sentiment in the market. The performance of major sectors was mixed, with noticeable divergence in retail, internet content, and information sectors, while some leading stocks in technology and life sciences were active. Alibaba rose by 0.55%, attracting significant attention from investors; Tencent Holdings and WuXi AppTec fell by 1.13% and 1.85%, respectively. On the macro front, the market is focused on important economic data, with funds primarily engaged in structural rotation amid a cautious atmosphere

- The Hong Kong stock market showed slight adjustments, with the Hang Seng Index down 0.54%, reflecting cautious investor sentiment amid fluctuations in economic data and demand.  
- Retail and internet sectors exhibited mixed performances, with companies like Alibaba gaining while others like JD.com and Tencent faced declines, indicating weak consumer momentum.  
- Notable gainers included MINIMAX-WP rising 16.48% after announcing AI developments, and Zhaoyi Innovation up 14.25% due to a positive outlook in the memory market.

BILIBILI-W

Hang Seng Index

Hong Kong stock market intraday | The Hang Seng Index fell 0.54% during the session, the semiconductor sector surged in the afternoon, and MINIMAX continued to soar over 15%

HS-WXAT@EC2607B(18870.HK)

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

Top 5 HK Stock Gainers/Losers (>100B) (2.5)

OpenAI's CEO Altman: The company may seek partners or invest in AI drug discovery

New Drug Administration Implementation Regulations Released: Allowing Innovative Drugs to be Produced in Segments, Accelerating the Market Launch of Good Medicines

Hong Kong Stock Movement: INSILICO approved by FDA but fell 11.58%, leading stocks in the life sciences sector under pressure